Forte Biosciences (FBRX) Stock Price, News & Analysis

Company Overview

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $9.46 to $10.32
• 50-Day Range: $8.38 to $14.66
• 52-Week Range: $4.11 to $28.68
• Volume: 35,772 shs
• Average Volume: 42,125 shs
• Market Capitalization: $63.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $61.00
• Consensus Rating: Buy

Forte Biosciences Stock Analysis - MarketRank™

Forte Biosciences scored higher than 62% of companies evaluated by MarketBeat, and ranked 356th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Forte Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Forte Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Forte Biosciences are expected to grow in the coming year, from ($12.12) to ($3.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Forte Biosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Forte Biosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Forte Biosciences has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.16% of the float of Forte Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Forte Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forte Biosciences has recently decreased by 5.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Forte Biosciences does not currently pay a dividend.

Dividend Growth

Forte Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.16% of the float of Forte Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Forte Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forte Biosciences has recently decreased by 5.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Forte Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Forte Biosciences is held by insiders.

Percentage Held by Institutions

77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FBRX Stock Analysis - Frequently Asked Questions

How have FBRX shares performed this year?

Forte Biosciences' stock was trading at $22.71 at the start of the year. Since then, FBRX shares have decreased by 57.7% and is now trading at $9.61.

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) posted its earnings results on Thursday, May, 15th. The company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.48.

Who are Forte Biosciences' major shareholders?

Forte Biosciences' top institutional investors include Tybourne Capital Management HK Ltd. (11.95%), Envestnet Asset Management Inc. (0.29%) and AlphaQuest LLC (0.26%). Insiders that own company stock include Paul A Wagner and Antony A Riley.
View institutional ownership trends.

How do I buy shares of Forte Biosciences?

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), QUALCOMM (QCOM), Avino Silver & Gold Mines (ASM), Meta Platforms (META) and Zoom Communications (ZM).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBRX
• CIK: 1419041
• Web: www.fortebiorx.com
• Phone: (310) 618-6994
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Forte Biosciences: $61.00
• High Price Target: $61.00
• Low Price Target: $61.00
• Potential Upside/Downside: +534.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -149.15%
• Return on Assets: -114.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 5.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.21 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: 6,580,000
• Free Float: 6,195,000
• Market Cap: $63.23 million
• Optionable: Optionable
• Beta: 2.91